本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Redhill Biopharma Ltd

0.6449
-0.0084-1.29%
盤後0.5802-0.0647-10.03%19:56 EDT
成交量:26.58萬
成交額:17.52萬
市值:392.16萬
市盈率:-4.75
高:0.6799
開:0.6550
低:0.6200
收:0.6533
52周最高:2.79
52周最低:0.5700
股本:608.09萬
流通股本:501.95萬
量比:0.73
換手率:5.29%
股息:- -
股息率:- -
每股收益(TTM):-0.1358
每股收益(LYR):-0.1358
淨資產收益率:-1708.61%
總資產收益率:-22.79%
市淨率:0.92
市盈率(LYR):-4.75

資料載入中...

公司資料

公司名字:
Redhill Biopharma Ltd
交易所:
NASDAQ
成立時間:
2009
員工人數:
13
公司地址:
21 Ha’arba’a Street,Tel Aviv-Yafo,Israel
郵編:
6473921
傳真:
972 3 541 3144
簡介:
Redhill Biopharma Ltd.於2009年8月3日註冊成立。該公司是一家專業生物製藥公司,主要專註於美國胃腸道疾病、傳染病和腫瘤藥物的開發和商業化。該公司與Cumberland合作在美國商業化其胃腸道相關產品Talicia,並擁有包括opaganib和RHB-107在內的臨床階段治療候選藥物管線。

董事

名稱
職位
Dror Ben Asher
Chairman of the Board and Chief Executive Officer and Director
Kenneth Reed
Independent Director
Ofer Tsimchi
Independent Director
Rick D. Scruggs
Chief Commercial Officer and Director
Roni Mamluk
Independent Director
Shmuel Cabilly
Independent Director

股東

名稱
職位
Dror Ben Asher
Chairman of the Board and Chief Executive Officer and Director
Gilead Raday
Chief Operating Officer
Razi Ingber
Chief Financial Officer
Adi Frish
Chief Corporate and Business Development Officer
Guy Goldberg
Chief Business Officer
Rick D. Scruggs
Chief Commercial Officer and Director